Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
Austin G. Duffy(National Institutes of Health), Tim F. Greten(National Institutes of Health), David Venzon(National Institutes of Health), Firouzeh Korangy(Center for Experimental and Clinical Infection Research), Bradford J. Wood(National Institutes of Health Clinical Center), Mei ElGindi(National Institutes of Health), Seth M. Steinberg(National Cancer Institute), Oxana Makorova-Rusher(National Institutes of Health), Susanna V. Ulahannan(National Institutes of Health), Aradhana M. Venkatesan(National Institutes of Health), Nadine Abi‐Jaoudeh(National Institutes of Health), Jeremy L. Davis(University of Maryland, Baltimore), Theo Heller(National Institutes of Health), Venkatesh Krishnasamy(National Institutes of Health), Heiner Wedemeyer(Medizinische Hochschule Hannover), William D. Figg(National Cancer Institute), Drew Pratt(National Institutes of Health), Osama E. Rahma(Dana-Farber/Harvard Cancer Center), Elliot Levy(National Institutes of Health), Ashish Uppala(National Institutes of Health), Marybeth S. Hughes(Eastern Virginia Medical School), David E. Kleiner
Cited by 817
Related Papers
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
|New England Journal of Medicine|2010|3.3k
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
|The Lancet|2014|2.2k
Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease
|New England Journal of Medicine|2021|1.1k